Prostate cancer is a type of cancer that develops in the prostate gland, which is an important part of the male reproductive system. However, transgender women who have undergone gender-affirming hormone therapy and/or gender confirmation surgery may still have a prostate gland.
Although the use of hormone therapy to suppress testosterone levels can reduce the size of the prostate gland and the risk of developing prostate cancer, transgender women still have a small risk of developing this type of cancer.
One study published in the Journal of Urology found that transgender women who had undergone gender-affirming surgery had a lower incidence of prostate cancer compared to cisgender men, but the risk was still present. The study also found that transgender women who had undergone gender-affirming hormone therapy had a lower risk of prostate cancer compared to cisgender men.
It is important for transgender women to discuss their risk for prostate cancer with their healthcare provider and receive appropriate screening and monitoring based on their individual risk factors.
In summary, while prostate cancer is more commonly associated with cisgender men, transgender women may still have a prostate gland and a small risk of developing prostate cancer, making it important for them to receive proper medical care and monitoring.